Overcoming Translational Roadblocks to Accelerate Allogeneic Therapies to Clinic
- Identify current roadblocks in the progression of allogeneic therapies to clinic
- Share actionable strategies to overcome translational and regulatory hurdles
- Highlight Atara Biotherapeutics’ ATA3219 targeting lupus to inform the next steps toward market readiness